Edward Nash
Stock Analyst at Canaccord Genuity
(3.44)
# 951
Out of 5,157 analysts
72
Total ratings
46.58%
Success rate
5.95%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $62 | $47.02 | +31.86% | 1 | Feb 19, 2026 | |
| CORT Corcept Therapeutics | Maintains: Buy | $99 → $100 | $33.54 | +198.15% | 12 | Jan 23, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.47 | +912.15% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $432.78 | +35.63% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $34.66 | +208.71% | 2 | Nov 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $5.53 | +406.33% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $6.58 | +203.95% | 3 | Sep 30, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $31.15 | +99.04% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $28.63 | +64.16% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.33 | +576.69% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.39 | +187.77% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $75.37 | +18.08% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.06 | +654.72% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.21 | +429.60% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.33 | -39.94% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.61 | +29,282.96% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.20 | +409.80% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $22.84 | +259.02% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $18.26 | +162.87% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.14 | +12,545.91% | 1 | Nov 8, 2017 |
Kiniksa Pharmaceuticals International,
Feb 19, 2026
Initiates: Buy
Price Target: $62
Current: $47.02
Upside: +31.86%
Corcept Therapeutics
Jan 23, 2026
Maintains: Buy
Price Target: $99 → $100
Current: $33.54
Upside: +198.15%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.47
Upside: +912.15%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $432.78
Upside: +35.63%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $34.66
Upside: +208.71%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $5.53
Upside: +406.33%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $6.58
Upside: +203.95%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $31.15
Upside: +99.04%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $28.63
Upside: +64.16%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.33
Upside: +576.69%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.39
Upside: +187.77%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $75.37
Upside: +18.08%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.06
Upside: +654.72%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.21
Upside: +429.60%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.33
Upside: -39.94%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.61
Upside: +29,282.96%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.20
Upside: +409.80%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $22.84
Upside: +259.02%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $18.26
Upside: +162.87%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.14
Upside: +12,545.91%